Rhabdomyolysis associated with concomitant use of atorvastatin and cyclosporine

Annals of Pharmacotherapy

Volumn 33, Issue 11, 1999, Pages 1176-1779

  Maltz, Helene C ^a   Balog, Denise L ^b   Cheigh, Jhoong S ^c  

^a ST JOHN'S UNIVERSITY   (United States)

^b NEW YORK PRESBYTERIAN HOSPITAL   (United States)

^c Department of Obstetrics Gynecology   (United States)

Author keywords

Atorvastatin; Cyclosporine; Rhabdomyolysis

Indexed keywords

3 HYDROXY 3 METHYLGLUTARYL COENZYME A; ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; ATORVASTATIN; CREATINE KINASE; CYCLOSPORIN; LACTATE DEHYDROGENASE;

ADULT; ARTICLE; CASE REPORT; COMBINATION CHEMOTHERAPY; DRUG POTENTIATION; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; KIDNEY TRANSPLANTATION; PRIORITY JOURNAL; RHABDOMYOLYSIS; SYSTEMIC LUPUS ERYTHEMATOSUS;

ANTICHOLESTEREMIC AGENTS; CADAVER; CYCLOSPORINE; DRUG INTERACTIONS; ENZYME TESTS; FEMALE; HEPTANOIC ACIDS; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; IMMUNOSUPPRESSIVE AGENTS; KIDNEY TRANSPLANTATION; MIDDLE AGED; PYRROLES; RHABDOMYOLYSIS;

EID: 0032743429     PISSN: 10600280     EISSN: None     Source Type: Journal    
DOI: 10.1345/aph.19039     Document Type: Article

References (21)

1. Jones P, Kafonek S, Laurora I, Hunninghake D. Comparative dose efficacy study of atorvastatin versus simvastatin, pravastatin, lovastatin, and fluvastatin in patients with hypercholesterolemia (the CURVES study). Am J Cardiol 1998;81:582-7.
2. Hunninghake D, Bakker-Arkema RG, Wigand JP, Drehobl M, Schrott H, Early JL, et al. Treating to meet NCEP-recommended LDL cholesterol concentrations with atorvastatin, fluvastatin, lovastatin, or simvastatin in patients with risk factors for coronary heart disease. J Fam Pract 1998;47:349-56.
3. Kobashigawa JA, Kasiske BL. Hyperlipidemia in solid organ transplantation. Transplantation 1997;63:331-8.
4. Li PK, Mak TW, Wang AY, Lee YT, Leung CB, Lui SF, et al. The interaction of fluvastatin and cyclosporin A in renal transplant patients. Int J Clin Pharmacol Ther 1995;33:246-8.
5. Kirk JK, Dupuis RE. Approaches to the treatment of hyperlipidemia in the solid organ transplant recipient. Ann Pharmacother 1995;29:879-91.
6. Yoshimura N, Oka T, Okamoto M, Ohmo Y. The effects of pravastatin on hyperlipidemia in renal transplant recipients. Transplantation 1992; 53:94-9.
7. Kobashigawa JA, Katznelson S, Laks H, Johnson JA, Yeatman L, Wang XM, et al. Effect of pravastatin on outcomes after cardiac transplantation. N Engl J Med 1995;333:621-7.
8. Ensley RD, Hammond EH, Renlund DG, Yowell RL, Bristow MR, DeWitt CW, et al. Clinical manifestations of vascular rejection in cardiac transplantation. Transplant Proc 1991;23:1130-2.
9. Katznelson S, Wilkinson AH, Kobashigawa JA, Wang XM, Chia D, Ozawa M, et al. The effect of pravastatin on acute rejection after kidney transplantation - a pilot study. Transplantation 1996;61:1469-74.
10. Southworth MR, Mauro VF. The use of HMG-CoA reductase inhibitors to prevent accelerated graft atherosclerosis in heart transplant patients. Ann Pharmacother 1997;31:489-91.
11. Goldberg RB, Roth D. A preliminary report of the safety and efficacy of fluvastatin for hypercholesterolemia in renal transplant patients receiving cyclosporine. Am J Cardiol 1995;76:107A-9A.
12. Folkers K, Langsjoen P, Willis R, Richardson P, Xia LJ, Ye CQ, et al. Lovastatin decreases coenzyme Q levels in humans. Proc Natl Acad Sci 1990;87:8931-4.
13. Ghirlanda G, Oradei A, Manto A, Lippa S, Uccioli L, Caputo S, et al. Evidence of plasma CoQ10-lowering effect by HMG-CoA reductase inhibitors: a double-blind, placebo-controlled study. J Clin Pharmacol 1993;33:226-9.
14. Mortensen SA, Leth A, Agner E, Rohde M. Dose-related decrease of serum coenzyme Q10 during treatment with HMG-CoA reductase inhibitors. Mol Aspects Med 1997;18(suppl):S137-44.
15. Holdaas H, Hartmann A, Stenstrom J, Dahl KJ, Borge M, Pfister P. Effect of fluvastatin for safely lowering atherogenic lipids in renal transplant patients receiving cyclosporine. Am J Cardiol 1995;76:102A-6A.
16. Austen JL, Shifrin FA, Bartucci MR, Knauss TC, Schulak JA, Hricik DE. Effects of fluvastatin on hyperlipidemia after renal transplantation: influence of steroid therapy. Ann Pharmacother 1996;30:1386-9.
17. Goldberg R, Roth D. Evaluation of fluvastatin in the treatment of hypercholesterolemia in renal transplant recipients taking cyclosporine. Transplantation 1996;62:1559-64.
18. East C, Alivizatos PA, Grundy SM, Jones PH, Farmer JA. Rhabdomyolysis in patients receiving lovastatin after cardiac transplantation. N Engl J Med 1988;318:47-8.
19. Product information: Lipitor (atorvastatin). Morris Plains, NJ: Parke-Davis, 1996.
20. Lea AP, McTavish D. Atorvastatin: a review of its pharmacology and therapeutic potential in the management of hyperlipidemias. Drugs 1997; 53:828-47.
21. Petri M. Treatment of systemic lupus erythematosus: an update. Am Fam Physician 1998;57:2753-60.